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The use of medications that further suppress the
immune system, such as biologic agents, further in-
creases the risk of developing an adverse event
(AE). For these reasons, it is important to know the
long-term safety of biologic drugs, with particular
regard to the rate of infections, in order to ensure
that treatments are both effective and safe over an
extended period of time. 
The aim of this report is to evaluate data assessing
the safety (based on serious AEs, SIEs and malig-
nancy) of rituximab (RTX) use in patients with RA,
both in the short-term, after a single course, and in
the medium-term (e.g. <10 years), after multiple
courses. 
Data on safety from clinical trials after a single
course in patients with RA already treated (with
TNF-antagonists (a-TNF) and/or methotrexate
(MTX)) and not previously treated 
Data obtained from three (a phase IIa (5), a phase
IIb (6), a phase III (7)) clinical trials in RA patients
who have an inadequate response to ≥1 a-TNF
and/or MTX show that RTX is well tolerated.
In the 6-month REFLEX study (7) patients with ac-
tive RA and an inadequate response to 1 or more
a-TNF agents were randomized to receive intra-
venous RTX (1 course, consisting of 2 infusions of
INTRODUCTION
Patients with rheumatoid arthritis (RA) are at in-creased risk of manifestations such as serious
infectious events (SIEs), malignancies and cardio-
vascular disease (1). Moreover, a long administra-
tion of drugs is required in this chronic disease, a
condition that is responsible of a greater risk of
side effects. 
As an example, there is an almost 2-fold greater
risk on a SIE in patients with RA than in general
population (2). Furthermore bacterial infection, one
of the leading cause of morbidity and mortality in
RA patients (3), is not an uncommon side effect of
therapy. In addition, the use of corticosteroids, even
at low doses (10 mg per day or less), utilized in ap-
proximately 65% of patients in randomized clini-
cal trials is an important contributory factor to the
increased prevalence of SIEs among RA patients
(2, 4).
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RIASSUNTO
La artrite reumatoide è una malattia cronica che predispone alla comparsa di complicanze rappresentate da malat-
tie infettive, neoplasie e malattie cardiovascolari. Il rischio è aumentato dalla necessità di assumere a lungo farmaci
immunomodulatori, quali ad esempio i farmaci biotecnologici.
La sicurezza del rituximab è stata valutata in un periodo di tempo medio (non superiore ai 10 anni) e i dati disponi-
bili sono rassicuranti. Nei trials clinici condotti sia in pazienti già trattati (con antagonisti del TNF e/o con methotr-
exate) sia in pazienti naive è emerso che il rituximab è tollerato anche dopo diversi cicli di terapia. La percentuale
totale di eventi avversi è infatti rimasta stabile nei vari cicli. L’evento avverso più frequente era rappresentato dalla
comparsa di reazioni infusionali. La percentuale di infezioni serie non aumentava dopo diversi cicli.
I dati ottenuti da esperienze condotte nella vita quotidiana confermano il buon profilo di tollerabilità.
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1,000 mg each) or placebo, both with background
MTX. The overall incidence of AEs (Table I) oc-
curring in patients receiving RTX (85%) was sim-
ilar to that observed in patients receiving placebo
(88%). Infusion-related reactions (IRR) (defined
as any AE reported during or within 24 hours of in-
fusion) were higher with rituximab versus placebo
(29% versus 23%, respectively) during or follow-
ing the first infusion. The majority of these IRR (e.
g. nasopharyngitis, pyrexia, hypertension and dizzi-
ness) were of mild-to-moderate intensity and re-
duced with further infusions. The signs and symp-
toms of acute infusion reactions (e. g. pruritus, ur-
ticaria/rash, angioedema, fever, chills, rigors,
sneezing, throat irritation/tightness, cough, bron-
chospasm, with or without hypotension or hyper-
tension) were experienced by a greater proportion
of rituximab-treated patients (23%) than placebo-
treated patients (18%) during the first infusion. 
However, the likelihood of patients experiencing an
IRR diminished with the second infusion, where
acute infusion reactions occurred in fewer patients
receiving RTX (8%) than placebo (11%). Two
RTX-treated patients experienced acute infusion
reactions that were considered serious adverse
events (SAEs) (anaphylaxis and hypertension, re-
spectively), but most infusion reactions were mild
or moderate in severity (National Cancer Institute
Common Toxicity Criteria (NCI CTC) grade 1 or
2). Premedication with intravenous methylpred-
nisolone (100 mg 30 minutes before each infusion)
significantly reduced both the incidence and sever-
ity of acute infusion reactions. 
For patients who experienced an infusion reaction,
the recommended treatment included aceta-
minophen/paracetamol plus intramuscular or slow
intravenous administration of antihistamine
(diphenhydramine HCl) and/or a bronchodilator, if
indicated. In patients who experienced a severe in-
fusion-related reaction, the infusion was immedi-
ately interrupted and symptomatic treatment was
initiated. After all symptoms disappeared, the in-
fusion was restarted at half the rate that had pre-
cipitated the reaction.
Two patients in the placebo group withdrew from
the study because of AEs (1 because of gastric can-
cer and 1 because of thrombocytosis). Eight pa-
tients in the RTX group withdrew because of AEs,
5 because of IRR during the first infusion (ana-
phylactic reaction, urticaria, laryngeal edema, and
cough and hoarseness) and 3 because of other
events (cardiac tamponade, spontaneous abortion,
and progressive RA). SAEs occurred at a higher in-
cidence in placebo-treated patients (10%) than in
rituximab-treated patients (7%) (Table I). There
were no events that raised significant safety con-
cerns. As for infectious episodes, treatment with
RTX may increase the risk of infective complica-
tions because of a rapid depletion of normal B cells
which can last for 2 to 6 months. However, serum
immunoglobulin levels seem to remain stable after
a conventional cycle of treatment and it is not con-
sistently associated with an increased risk of bac-
terial infections. 
The observed incidence of infections over 24
weeks in the REFLEX study was slightly higher in
Table 1 - Summary of adverse events.
Single course* Multiple courses**
Placebo/MTX RTX/MTX Course 1 Course 2 Course 3 Course 4  Course 5 
n = 209 n = 308 n = 2578 n = 1890 n = 1043 n = 425 n = 133
Any AE n (%) 183 (88) 261 (85) 2145 (83) 1391 (74) 675 (65) 248 (58) 81 (61)
Serious AEs n (%) 21 (10) 23 (7) 320 (12) 197 (10) 79 (8) 21 (5) 11 (8)
Infections/100 pt-yrs 154.6 138.2 98.36 95.20 101.12 99.36 88.73
Serious infections/100 pt-yrs 3.7 5.2 4.48 3.81 4.84 3.79 6.83
*Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T,
Totoritis MC. Arthritis Rheum 2006; 54: 2793-2806. **van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleischmann R, Furst DE, Macey K,
Sweetser M, Kelman A, Rao R. J Rheumatol 2010; 37: 558-567.
A serious AEs was defined as any experience that was fatal, immediately life-threatening, required hospitalization or prolongation of an existing hospitali-
zation (with the exception of hospitalization for exacerbations of articular or periarticular manifestations of RA), resulted in persistent or significant disabi-
lity/incapacity, was a congenital anomaly/birth defect, was medically significant, or required intervention to prevent 1 or more of the outcomes listed abo-
ve. Serious infection events were pre-defined as infections that required intravenous antibiotics or met the regulatory criteria for a serious adverse event,
where at least one of the following applied: required inpatient hospitalization or prolongation of an existing hospitalization, were immediately life-threa-
tening, resulted in persistent or significant disability or incapacity, were medically significant, where an intervention was required to prevent one of the
previously mentioned outcomes, or were fatal.
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RTX-treated patients (41%) than in placebo-treat-
ed patients (38%). Conversely, however, when the
duration of response was taken into consideration,
the overall infection rate per 100 patient-years was
slightly higher in placebo-treated patients (154.6
per 100 patient-years) than in rituximab-treated pa-
tients (138.2 per 100 patient-years). Rates of seri-
ous infections were 3.7 per 100 patient-years (three
serious infections) for placebo versus a marginal-
ly higher 5.2 per 100 patient-years for rituximab
(seven serious infections). Importantly, there were
no reports of tuberculosis or opportunistic infec-
tions over the 24 weeks of this study.
The tolerability data from the Phase IIa (5) and
phase IIb DANCER (6) are consistent with those
reported in the REFLEX study (7).
It is important to remember that in patients with
lymphoma there have been reports of reactivation
of hepatitis B and exacerbation of hepatitis C
(8,9,10). Sera et al. (10) reported an HBV surface
antigen (HBsAg)-negative, anti-HBV surface anti-
body (anti-HBsAb)-positive patient converting to
HBsAg-positive status with acute hepatitis during
rituximab therapy, and they suggested prophylax-
is with lamivudine in both HBsAg-positive and
HBsAg negative (with evidence of previous infec-
tion, i.e., anti-HBV core antibody) prior to initia-
tion of rituximab therapy, despite the presence of
anti-HBsAb. Thus, RTX-based therapy may cause
serious HBV-related complications and even death
in both HBsAg-positive and HBsAg-negative pa-
tients (11). Therefore, baseline screening for HBV
before initiation of RTX is mandatory.
In patients with early active RA not previously
treated with MTX (MTX-naïve) (12), safety data
at 24 weeks were consistent with those previously
reported. The rate of serious infections in patients
treated with infusions of 2 x 500 mg or 2 x 1,000
mg given every two weeks was 6.09, 4.61 and 3.73
events/100 pt-years in the placebo + MTX, RTX (2
x 500 mg) and RTX (2 x 1000) groups, respec-
tively.
Data on safety from clinical trials after multiple
courses in patients with active RA already
treated (with a-TNF and/or MTX)
Patients with active RA a-TNF and/or MTX-resis-
tant who received ≥2 courses of RTX during par-
ticipation in one of 9 trials in an international clin-
ical trial program were included in an analysis that
involved a larger number of RTX-treated patients
than previously reported, followed for multiple
courses (13). Data were obtained from patients who
had been treated in the following studies: phase IIa
(5), phase IIb (6), phase III (7), REFLEX extension
(14, 15), DANCER extension, SERENE (16),
MIRROR (17), SUNRISE (18), SIERRA (19). A
single course of treatment consisted of infusions of
2x500 mg or 2x1,000 mg, given two weeks apart.
All patients were offered retreatment with RTX
based on clinical need. 
Patients receiving placebo during placebo-con-
trolled study periods were pooled to provide a
placebo population. In the overall cohort there were
patients who had undergone up to 10 courses of
RTX. This analysis, however, only included pa-
tients with up to five courses, because the numbers
of patients having more than five were small and
the confidence intervals of point estimates were
wide.
At data cut-off (November, 2007), a total of 2,578
patients were included, with 5,013.5 patient-years
(pt-yrs) of observation, that received multiple
courses of treatment (1,890 patients received ≥2
courses; 1,043 patients received ≥3 courses; 425
patients received ≥4 courses, and 133 patients re-
ceived ≥5 courses) over a 6-year follow-up (Table
I). Most study participants were woman, mean age
was 53 years, and disease duration averaged 10
years. They have received a mean of three previ-
ous biologic or disease-modifying drugs (other than
MTX), and more than half had previously been
treated with a tumor necrosis factor inhibitor. 
The rates for adverse events, serious adverse
events, and overall infection rates remained stable
following each course.
The overall rate of AEs was highest for the first
course (83%), declining with the second course
(74%), and remaining stable thereafter (65%, 58%
and 61% respectively for the third, fourth and fifth
course) (Table I). 
The most frequent AE was IRR (35% of patients;
<1% considered serious). These reactions were ob-
served in 25% of patients during the first course,
typically manifesting as mild-to-moderate
headache, pruritus, hypertension, and rash. Some
9% of patients required slowing or stopping the in-
fusion because of these reactions during the first
course. By the fifth course, all patients were toler-
ating the infusion, a pattern supporting the hy-
pothesis that cytokine release syndrome is less like-
ly with additional courses because of a lower B-cell
load.
A total of 123 patients (5%) withdrew from the
study because of AEs. The rate of serious AEs re-
mained stable following each course of treatment
for up to five years (Table I). The most frequently
serious AEs reported were: pneumonia (1%), falls
(1%), myocardial infarction (0,9%). The rate of
myocardial infarction was an expected 0.56 per
100 patient-years, generally occurring in patients
with risk factors. This was consistent with rates re-
ported for other rheumatoid arthritis populations. 
Overall serum immunoglobulin levels decreased
during follow-up, with 5% of patients having lev-
els of IgG below the lower limit of normal on at
least one occasion. 
Classical observations have shown that IgG is the
most important among serum immunoglobulins for
protective immunity and that patients with low lev-
els of IgG are at increased risk of serious infections.
In this patient cohort, the rates of serious infec-
tions did not significantly increase when low IgG
levels were detected. Older age and the concomi-
tant use of steroids can contribute to decreases in
IgG, and because corticosteroids were permitted
in the clinical trials, it is unclear to what degree rit-
uximab caused the fall in immunoglobulins. Irre-
spective of the underlying mechanisms for patients
who had low levels of IgG, this subset of patients
may be at higher risk for infections and should be
monitored closely.
A total of 65% of patients experienced some type
of infection (most commonly nasopharyngitis and
upper respiratory tract infection) with a rate of 97.7
per 100 patient-years. Serious infections (such as
pneumonia, cellulitis, and urinary tract infections)
rates averaged 4.23 per 100 patient years for treat-
ment courses one through four, but increased to
6.83 per 100 patient years with 5 courses of treat-
ment (Table I). 
There were no cases of serious opportunistic in-
fections during the analysis period. 
The overall incidence of malignancies other than
non-melanoma skin cancer was 0.84 per 100 pa-
tient-years, and the adjusted standardized incidence
ratio (SIR) compared with the general U. S. popu-
lation was 1.05 (95% CI 0.76 to 1.42). Thirty
deaths occurred, and the adjusted standardized
mortality rate compared with the overall U.S. pop-
ulation was 0.83 (95% CI 0.56 to 1.18). Therefore,
the results from this international six year follow-
up program showed that RTX treatment was well
tolerated for repeat and/or long term treatments
with multiple courses in patients with advanced
rheumatoid arthritis, with no increase in serious
adverse events or serious infections. Authors point-
ed out that the study had limitations, such as pool-
ing of information from trials in which number of
treatment courses, disease status, and doses of RTX
differed. The data were also constrained by the in-
clusion and exclusion criteria of the clinical trials. 
An extension of these data were presented at the
October 2009 American College of Rheumatology
meeting (20). As of September 2008, 3.095 pa-
tients had been treated with RTX providing 7.198
pt-years (pt-yrs) of exposure. Over 750 patients
had been followed for >3 years with 2.365, 1.581,
1.038 and 497 pts receiving ≥2, ≥3, ≥4 and ≥5
courses, respectively. 
Other than IRR, the safety profile of RTX was sim-
ilar to the pooled placebo population. In the RTX
group, the most frequent AE was IRR (35%), most
of which were NCI CTC grade 1 or 2 and occurred
after the first infusion of the first course (23%),
with <1% considered serious. The rate of serious
infection was 4.25 events/100 pt-yrs and was com-
parable to that observed in the placebo population
(4.33 events/100 pt-yrs). The most frequent serious
infections were of the lower respiratory tract, pre-
dominantly pneumonia (1%). No cases of TB or re-
activation of hepatitis B were reported. Serious op-
portunistic infections were uncommon, but in-
cluded one confirmed case of Pneumocystis jirove-
ci pneumonia in each of the RTX and pooled place-
bo groups and one case of progressive multifocal
leukoencephalopathy (PML) in the RTX group. In
this patient PML occurred in 2008, 18 months af-
ter receiving the last dose of RTX. Patient received
also corticosteroids and MTX. 
The casual relationship of PML to RTX in this case
was unclear due to recognized risk factors includ-
ing carcinoma of the oropharynx treated by
chemoradiotherapy. Rates of myocardial infarction
(MI) and stroke were consistent with the general
RA population. The SIR for malignancy compared
with the Surveillance, Epidemiology and End Re-
sults (SEER) 2008 database was 1.06 (95% CI
0.81-1.37). The most frequently reported malig-
nancy (excluding non-melanoma skin cancer) was
breast cancer (SIR 0.69; 95% CI 0.35-1.24). Au-
thors concluded that in prolonged follow-up of RA
pts treated with RTX in clinical trials, RTX has re-
mained well tolerated over multiple courses with a
stable safety profile similar to the pooled placebo
population.
On October 2009, PML has been reported in a third
patient with RA, occurring within 6 months after
RTX treatment. Unlike both prior cases in patients
with RA, the third patient had not previously treat-
ed with a-TNF and therefore is the first case of
PML in a patient with RA treated with RTX. The
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risk of PML associated with rituximab remains un-
certain because definite cases outside clinical tri-
als are rare (21).
Data on safety from “real-life” after multiple
courses in patients with active RA already
treated (with a-TNF and/or MTX)
Patients enrolled in clinical trials may differ from
patients who do not meet inclusion/exclusion cri-
teria. Experiences with RTX (two infusions 1000
mg each, a fortnight apart) in “real-life” setting
were conducted in patients with RA resistant to
more than two a-TNF drugs. Re-treatment with a
second cycle of RTX was offered if they had re-
sponded to the earlier one but flared. RTX was safe
with no major side effects. Re-treatment with RTX
was safe too (22). RTX is well tolerated in every-
day clinical practice also in patients where a-TNF
therapy is either unavailable or relatively con-
traindicated (23).
In conclusion, RTX is globally well-tolerated either
in the short-term (e. g. after a single course), either
in the medium-term (e. g. after multiple courses in
a period <10 yrs), either in a-TNF and/or MTX re-
sistant either in MTX-naïve RA patients. Six-year
follow-up data prove that RTX continues to be
well-tolerated over several courses of treatment
with a low rate of adverse events and infections
similarly to other biologic agents used to treat RA
(13) (12). Therefore, in a long-term condition like
RA, treatment with RTX is safe over an extended
period of time.
SUMMARY
Rheumatoid arthritis (RA) is a chronic disease that requires a long-term administration of immunomodulatory drugs
with a greater risk of side effects like malignancies, serious infections and cardiovascular diseases. Furthermore, pa-
tients with RA are more prone than general population to these manifestations.
Safety of rituximab has been evaluated in the short-term (6 months) and in the medium-term (up to 10 years) in pa-
tients who had been previously treated with antagonists of tumor necrosis factor (a-TNF) and/or with methotrexate
(MTX) and in patients who were not.
Data obtained from clinical trials demonstrated that rituximab is well tolerated either after a single course or after mul-
tiple courses. The overall rate of adverse events (AEs) was stable after the first three courses. The most frequent ad-
verse event was infusion-related reactions (IRR). Serious infections did not increase after multiple courses.
Data from “real life” confirm that treatment with rituximab is well tolerated.
Parole chiave - Rituximab, artrite reumatoide, sicurezza, infezioni, neoplasie.
Key words - Rituximab, rheumatoid arthritis, safety, infections, malignancies.
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